Clinical Trials Logo

Lung Adenocarcinoma, Stage I clinical trials

View clinical trials related to Lung Adenocarcinoma, Stage I.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05830812 Recruiting - Clinical trials for Lung Adenocarcinoma, Stage I

Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma

Start date: January 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to improve the intraoperative diagnosis accuracy of invasiveness for small-sized lung adenocarcinoma by combining multi-modal information. The main question it aims to answer is whether multi-modal information have great value of prediction on the invasiveness for small-sized lung adenocarcinoma. Since a promising limited resection is largely based on intraoperative frozen section diagnosis, there is a growing demand on the high-accuracy of timely pathology diagnosis. The multi-modal information of participants will be collected retrospectively.

NCT ID: NCT04944173 Recruiting - Lung Cancer Clinical Trials

SCION: SABR and Checkpoint Inhibition Of NSCLC

SCION
Start date: August 11, 2023
Phase: Phase 2
Study type: Interventional

The SCION Trial is a clinical trial in patients with early stage non-small cell lung cancer. The purpose of the trial is to investigate whether it is safe and effective to combine standard radiation treatment with a drug called durvalumab, a type of immunotherapy. In addition, the study will use a blood test to look for cancer cell DNA to determine how long treatment with durvalumab should last. Both the use of durvalumab and the use of the blood test are new strategies for managing early stage non-small cell lung cancer.

NCT ID: NCT03351842 Recruiting - Treatment Clinical Trials

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

NCT ID: NCT03254004 Recruiting - Clinical trials for Lung Adenocarcinoma, Stage I

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

Start date: October 8, 2018
Phase: Phase 2
Study type: Interventional

A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks

NCT ID: NCT02951897 Recruiting - Treatment Clinical Trials

Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma

CTCs detection
Start date: April 2016
Phase: N/A
Study type: Interventional

In 2015-2016, 224,390 cases were newly diagnosed with lung cancer in USA. Of all the cases, 83% are non-small cell lung cancer (NSCLC). Currently, the 5-year survival rate of NSCLC patients is 21%, and more than 25% of early stage NSCLC patients, who have undergone surgical treatment, will have a relapse or progression. Circulating tumor cells (CTCs), which shed from the primary tumor into the vasculature or lymphatics, can be regarded as a new prognostic factors of metastatic process. Thus far, CTCs-detection technologies can be divided into epithelial cell adhesion molecule (EpCAM)-based detection methods, e.g., the widely used CellSearch® and Adnatest®,and EpCAM-independent detection methods, e.g., ISET® and ScreenCell®. Herein, the investigators used a newly established approach, i.e., CanPatrolTM to detect CTCs in early stage lung Adenocarcinoma cases. The investigator aim to explore whether CTCs detection prior to surgery can be contributive to the early diagnosis, or may help to predict the prognosis and guide the treatment strategy of early stage lung Adenocarcinoma.